Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s Brilique Triumphs As First Drug Through Germany’s New Pricing Process

This article was originally published in The Pink Sheet Daily

Executive Summary

Following negotiations, AstraZeneca’s clot buster Brilique has been awarded a price that has pleased both the manufacturer and health insurers – but industry as a whole remains skeptical of the system.

You may also be interested in...



AstraZeneca Blames Germany’s Tender System For Influenza Vaccine Shortages

AstraZeneca says that shortages of influenza vaccines in Germany are a direct result of the tendering process there, which has blocked the firm’s Fluenz nasal spray product from being prescribed in several federal states.

For Effient And Brilinta, A Formidable Competitor Grows More So

Plavix was a tough competitor before it went generic; now that cheap versions of the clot-buster are available, the market will prove even more challenging for the remaining branded antiplatelet drugs.

German Pricing Mechanism Adds Weak Economies, Could Spell Trouble For EU Industry

The decision by the German pharmaceutical arbitration committee to include countries such as Greece in a final pricing mechanism will cut German prices and may have a Europe-wide effect.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074225

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel